Caris Life Sciences (CAI) Cash from Investing Activities (2024 - 2026)

Caris Life Sciences' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$10.3 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 284.6% year-over-year to -$10.3 million in Q1 2026; TTM through Mar 2026 was -$23.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$16.3 million, down 130.72% from the prior year.
• Cash from Investing Activities retreated to -$10.3 million in Q1 2026 per CAI's latest filing, from -$5.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$1.4 million in Q2 2025 and bottomed at -$10.3 million in Q1 2026.
• The 3-year median for Cash from Investing Activities is -$2.7 million (2025), against an average of -$4.4 million.
• Biggest YoY gain for Cash from Investing Activities was 122.27% in 2025; the steepest drop was 288.13% in 2025.
• Year by year, Cash from Investing Activities stood at -$2.3 million in 2024, then plunged by 122.27% to -$5.1 million in 2025, then plunged by 103.18% to -$10.3 million in 2026.
• Per Business Quant, the three latest CAI Cash from Investing Activities figures stand at -$10.3 million (Q1 2026), -$5.1 million (Q4 2025), and -$7.1 million (Q3 2025).